(S)-(-)-Nadifloxacin

Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes[1].

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> Bacterial

Levonadifloxacin (32 μg/mL; 24 h) achieves a 90-99% intracellular reduction of MSSA and MRSA strains phagocytized in THP-1 monocytes with MICs of 0.03 μg/mL and 15.0 ng/mL[1].

Levonadifloxacin (12.5-400 mg/kg; s.c.; single dose) shows efficacy in vivo against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model[2]. Animal Model: Male/Female Swiss Albino mice (25-28 g) for plasma pharmacokinetic analyses[2] Dosage: 12.5, 25, 50, 100, 200, 300 and 400 mg/kg Administration: Subcutaneous injection; single dose; collected samples at 10 time points/dose (0.25, 0.5, 1, 2, 4, 6, 8, 10, 58 12 and 24 h post dose) Result: Dose (mg/kg) Cmax (mg/L) AUC0-24 h (mg·h/L) T1/2 (h) 12.5 4.37 7.30 1.79 25 8.71 15.75 1.48 50 19.21 33.36 1.48 100 38.65 70.86 1.76 200 77.29 145.48 1.69 300 92.46 286.19 2.44 400 115.16 393.52 1.74